Phase II evaluation of capecitabine in refractory nonsquamous cell carcinoma of the cervix: A Gynecologic Oncology Group Study

Keyphrases

• Cervical Carcinoma 100%
• Group Studies 100%
• Capecitabine 100%
• Non-squamous Cell Carcinoma 100%
• Gynecologic Oncology Group 100%
• Cervical Cancer 66%
• Chemotherapy 66%
• Non-squamous 66%
• Histologic 33%
• Radiation Therapy 33%
• Neurotoxicity 33%
• Bone Marrow 33%
• Initial Dose 33%
• Group Performance 33%
• Stable Disease 33%
• Consecutive Days 33%
• Chemotherapeutic Regimens 33%
• Neutropenia 33%
• Primary Cancer 33%
• Previously Treated 33%
• Dosing Schedule 33%
• Pulmonary Toxicity 33%
• Response Evaluation Criteria in Solid Tumors (RECIST) 33%
• Disease Response 33%
• No Response 33%
• Performance Status 33%
• Divided Dose 33%
• Multi-institutional Study 33%
• Cervical Cancer Patients 33%
• Renal Toxicity 33%
• Disease Assessment 33%

Medicine and Dentistry

• Carcinoma Cell 100%
• Cervix 100%
• Capecitabine 100%
• Gynecological Oncology 100%
• Cervical Cancer 66%
• Diseases 33%
• Malignant Neoplasm 33%
• Radiation Therapy 33%
• Primary Tumor 33%
• Nephrotoxicity 33%
• Chemotherapy 33%
• Pulmonary Toxicity 33%
• Neutropenia 33%
• Drug Dose Regimen 33%
• Response Evaluation Criteria in Solid Tumors 33%
• Disease Assessment 33%